

## ASX Announcement

29 August 2025

## FY25 Full Year Results and Operational Update

**ReNerve Limited** (ASX, "ReNerve" or "the **Company**"), a pioneering Australian medical device company developing innovative products for peripheral nerve injury ("PNI") repair, announces its results for the financial year ended 30 June 2025 (FY25).

ReNerve has reported strong financial and operational results for the 2025 financial year, with annual revenue up 53%. Through external partnerships and its own research and development program, the company has made significant progress in strengthening its product portfolio, with several new product ranges expected to be brought to market during FY26. The company's cash position remains solid following its IPO, providing a foundation for continued growth in its business.

### Company Highlights for FY25

- **Annual Revenue Growth:** Revenue increased 53% year-over-year, driven by growing adoption of the NervAlign® Nerve Cuff in the US market.
- **Product Validation:** During the year we saw the publication of strong clinical data demonstrating the superior effectiveness of the NervAlign® Nerve Cuff compared to the standard of care, with patients receiving ReNerve's Nerve Cuff benefiting from materially reduced pain and improved surgical outcomes.
- **Product Pipeline Progress:** During FY25, ReNerve entered a partnership with Berkeley Biologics to launch dermal and amniotic tissue products in the US. In addition, continued progress with the NervAlign® Nerve Conduit product range sees ReNerve on track for market entry in Q4 CY25.
- **International Expansion:** ReNerve has entered a partnership with NetCentrix Ventures to address India's US\$115M nerve repair market<sup>1</sup> and has secured regulatory approval for the NervAlign® Nerve Cuff in Bahrain and Thailand.
- **Strong Cash Position:** The Company's closing cash at 30 June was \$4.75M, ensuring a robust runway for planned R&D and commercialisation activities.

### Key Financials

Metric	FY25 Result	Change vs FY24
Revenue	53% YoY growth	+53%
Quarterly Revenue	+25% Q4 vs Q3	+25%
Closing Cash	\$4.75M	Strong position

<sup>1</sup> MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025



## Strategic & Corporate Developments

- The successful IPO in November 2024 raised \$7 million, transforming ReNerve's balance sheet.
- All convertible notes were converted to equity, resulting in net assets of nearly \$7 million and eliminating debt from the balance sheet.

## CEO Commentary

**Dr Julian Chick, CEO, stated:** *"ReNerve's momentum continued through FY2025 after another busy period for the company. Revenue continues to build and the partnership with Berkeley allows us to bring complementary products to market to further build on this growth."*

## Outlook

ReNerve anticipates continued company and revenue growth in FY26, supported by new product launches, further international expansion, and a strong financial platform to invest in research, regulatory pathways, and commercial execution. The company remains dedicated to advancing innovative therapies to address unmet needs in nerve repair and related tissue regeneration

- ENDS -

**This announcement has been approved for release by the Company's Board of Directors.**

**For further information and enquiries, please contact:**

**Dr Julian Chick**  
CEO & Managing Director  
ReNerve Ltd  
+61 (03) 9482 3940  
[info@renerve.com.au](mailto:info@renerve.com.au)

**Matthew Wright**  
Investor & Media Relations  
NWR Communications  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

## About ReNerve Limited (ASX:RNV)

**ReNerve Limited (ASX:RNV) aims to transform nerve repair and improve lives through breakthrough medical technology.** Founded by a neurosurgeon and MedTech researchers, ReNerve is a rapidly growing medical device company that aims to revolutionise peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injury repairs (PNI).

### Proven Clinical Success

A clinical study announced in March 2025 has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement for patients.

### Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product** -- A deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology and designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – Focused on the nerve graft market for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

### Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales. Our high-margin products are providing solutions for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.96 billion in 2024 and is projected to reach \$6.2 billion by 2031.<sup>2</sup>

---

<sup>2</sup> Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

## **Vision and Values**

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.